

## Cadila Healthcare Limited

Registered Office : Zydus Tower , Satellite Cross Roads, Ahmedabad - 380015.

Tel. No. (+91-79) 686 8100 Fax No. : (+91-79) 686 2365/66 Website : www.zyduscadila.com

	Unaudited [ Provisional ] Financial Results for the Quarter ended September 30, 2007.											
	CC	ONSOLIDATE	D		Sr.	No.	Particulars			COMPANY		
	Rupees in Millio	ons [ except	for share dat	a]				Rupees in Millions [ except for share data ]				
	Corresponding	Year to date	Year to date						Corresponding	Year to date	Year to date	
	3 months ended	figures for	figures for the	Previous					3 months ended	figures for	figures for the	Previous
3 months	in the previous	current period	previous year	Accounting				3 months	in the previous	current period	previous year	Accounting
ended	year	ended	ended	year ended				ended	year	ended	ended	year ended
30/09/2007	30/09/2006	30/09/2007	30/09/2006	31/03/2007				30/09/2007	30/09/2006	30/09/2007	30/09/2006	31/03/2007
[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[Audited]				[Unaudited]	[Unaudited]	[Unaudited]	[Unaudited]	[ Audited ]
					1		Sales & Income from operations :					
6214	4892	12069	9457	18747		А	Gross Sales	4458	4037	9103	7812	15014
246	219	492	422	892		В	Less : Excise Duty	224	217	440	420	877
5968	4673	11577	9035	17855		С	Net Sales	4234	3820	8663	7392	14137
129	75	242	172	433		D	Other Income from Operations	240	87	334	164	482
6097	4748	11819	9207	18288	1	Е	Total sales and other income from operations	4474	3907	8997	7556	14619
0	3	3	3	1	2		Other Income	61	107	167	212	522
6097	4751	11822	9210	18289	3		Total Income	4535	4014	9164	7768	15141
					4		Expenditure :					
(147)	(171)	(79)	(492)	(917)		А	Increase / [ Decrease ] in stock in trade & work in progress	(28)	(107)	59	(338)	(726)
1339	1062	2792	2090	4643		В	Consumption of materials	1142	910	2407	1922	4200
801	753	1374	1569	2646		С	Purchase of traded goods	453	581	825	1090	1775
772	515	1351	993	2110		D	Employees cost	476	434	930	827	1733
235	213	474	410	823		E	Depreciation & Amortisation	181	167	357	326	667
2015	1499	3952	3060	6285		F	Other Expenditure	1409	1252	2969	2540	4997
5015	3871	9864	7630	15590	1	G	Total Expenditure	3633	3237	7547	6367	12646
137	69	210	125	234	5	A	Interest & financial charges	80	47	132	96	187
(10)	(15)	(101)	(2)	(11)		В	[Gain ] on Exchange Rate Fluctuations on Foreign Currency Loar	(10)	(15)	(101)	(2)	(11)
127	54	109	123	223	1	С	Total Financial cost	70	32	31	94	176
24	0	24	(49)	(263)	6		Exceptional Expenses / [ Income ]	24	0	24	0	0
931	826	1825	1506	2739	7		Profit [+] / Loss [-] from Ordinary Activities before tax	808	745	1562	1307	2319
114	100	235	175	324	8		Tax expense	95	90	185	160	272
817	726	1590	1331	2415	9		Profit [+] / Loss [-] from Ordinary Activities after tax	713	655	1377	1147	2047
0	0	0	0	0	10		Extraordinary items [ net of tax expense Rs]	0	0	0	0	0
817	726	1590	1331	2415	11		Profit [+] / Loss [-] after tax	713	655	1377	1147	2047
(16)	(21)	(50)	(42)		12		Adjustments on consolidation	0	0	0	0	0
801	705	1540	1289	2338	13		Net Profit [+] / Loss [-] for the period	713	655	1377	1147	2047
628	628	628	628	628	12		Paid-up equity share capital [ Face Value Rs. 5 /- ]	628	628	628	628	628
020	020	020	020	8027	13		Reserves excluding Revaluation Reserve as per balance sheet	020	020	020	020	8195
				0027			of previous accounting year					0170
					14		Earnings Per Share [EPS] [For the period - not Annualised]:					
6.38	5.61	12.26	10.26	18.61		А	Basic and diluted EPS before Extraordinary items [ Rs. ]	5.68	5.21	10.96	9.13	16.30
6.38	5.61	12.26	10.26			В	Basic and diluted EPS after Extraordinary items [ Rs. ]	5.68	5.21	10.96	9.13	16.30
0.00	5.01	12.20	10.20	1 13.01	15	U	Public shareholding :	5.00	5.21	10.70	7.13	10.50
					15		- Number of shares	35150458	35150458	35150458	35150458	35150458
							- Percentage of Shareholding	27.98%	27.98%	27.98%	27.98%	27.98%
							r creentage of ondrenording	21.7070	27.7070	21.7070	21.7070	21.7070

Notes :

[1] Pursuant to the recent amendments to the Clause 41of the Listing Agreement, the company has opted to publish only the consolidated results of the company. Investors can view the standalone results of the company on the company's website: www.zyduscadila.com and/or on the websites of BSE [ bseindia.com ] and/or NSE [ www.nseindia.com ].

[2] The above results for the quarter and half year ended September 30, 2007 were reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on October 26, 2007. The statutory auditors of the Company have carried out a limited review of the unaudited financial results of the Company for the quarter and half year ended September 30, 2007.

[3] During the quarter, the Company has invested :

[A] Zydus International Pvt. Ltd., Ireland

[A]	Zydus International Pvt. Ltd., Ireland	Rs. 41 Mn.
[B]	Zydus BSV Pharma Pvt. Ltd. [ A Joint Venture Company ]	Rs. 7.5 Mn.
[ C ]	M/c 7vduc Hoalthcaro	Dc 77 E0 M

[C] M/s. Zydus Healthcare Rs. 77.50 Mn.

[4] The status of investor complaints :

Pending at the beginning of the quarter - Nil, received and disposed off during the quarter - 29, - pending at the end of the quarter - Nil.

[5] The Company has one segment of activity viz. " Pharmaceuticals ".

> By Order of the Board, For Cadila Healthcare Limited,

Ahmedabad, 26th October, 2007

Pankaj R. Patel Chairman & Managing Director